NASDAQ:CHRS
Coherus BioSciences Stock News
$1.82
-0.0600 (-3.19%)
At Close: May 31, 2024
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
06:43pm, Wednesday, 02'nd Aug 2023
Coherus BioSciences (CHRS) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.65 per share a year ago.
3 Hot Penny Stocks To Watch After TUP Stock Explodes, Again
01:48pm, Thursday, 27'th Jul 2023
Why would anyone want to buy penny stocks? They're extremely risky.
3 Hot Penny Stocks To Watch After TUP Stock Explodes, Again
01:48pm, Thursday, 27'th Jul 2023
Why would anyone want to buy penny stocks? They're extremely risky.
Best Penny Stocks To Buy Now? 3 To Watch Right Now
02:23pm, Friday, 07'th Jul 2023
Ever heard of penny stocks? If you're new to investing, you might be scratching your head.
Coherus: Why I Am Exiting, But Also Why You May Want To Hold On
12:40pm, Thursday, 06'th Jul 2023
Here, I discuss my reasons for exiting the stock. My reasons are more or less specific to my situation. Thus, we can agree to disagree without being too disagreeable about it.
Coherus BioSciences launches biosimilar version of AbbVie's blockbuster Humira
09:12am, Monday, 03'rd Jul 2023
Coherus BioSciences said on Monday it has launched a copycat version of AbbVie's Humira in the United States at a discount of over 85% to the blockbuster arthritis drug.
Surface Oncology stock flies on $65M stock-for-stock acquisition by Coherus BioSciences
11:01am, Friday, 16'th Jun 2023
Surface Oncology shares jumped by more than 16% on Friday morning after it was revealed the clinical-stage immuno-oncology (I-O) company is being acquired by Coherus BioSciences (NASDAQ:CHRS). The sto
Coherus BioSciences to launch Humira biosimilar at $995 per carton
09:24am, Thursday, 01'st Jun 2023
Coherus BioSciences Inc said on Thursday it plans to launch a biosimilar of AbbVie Inc's blockbuster arthritis drug Humira in July at a list price of $995 per carton, representing a discount of about
FDA flags issues at Coherus partner's China manufacturing site for cancer drug
01:37pm, Wednesday, 31'st May 2023
Coherus BioSciences Inc said on Wednesday that the U.S. Food and Drug Administration (FDA) flagged three observations at its partner Shanghai Junshi Biosciences Ltd's manufacturing site in China for i
Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)
08:56am, Friday, 26'th May 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Coherus BioSciences, Inc. (CHRS) Q1 2023 Earnings Call Transcript
09:40pm, Monday, 08'th May 2023
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Marek Ciszewski - Investor Relations Denny Lanfear - Chief Executive Officer There
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
07:02pm, Monday, 08'th May 2023
Coherus BioSciences (CHRS) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $1.24 per share a year ago.
Coherus BioSciences to Present at Upcoming Investor Conferences in May
04:30pm, Thursday, 04'th May 2023
REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor confere
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
04:07pm, Monday, 01'st May 2023
REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced its first quarter 2023 financial results will be released after market cl
Coherus Still Looks Good, Multiple Catalysts This Year (Rating Downgrade)
08:00am, Friday, 28'th Apr 2023
Coherus Still Looks Good, Multiple Catalysts This Year (Rating Downgrade).
